title: Assessment of whole body MRI and sestamibi technetium-99m bone marrow scan in prediction of multiple myeloma disease progression and outcome: a prospective comparative study.
abstract: OBJECTIVE
  This study aims primarily to determine whether whole body MRI (WB-MRI) and Sestamibi Technetium-99m-bone marrow (MIBI) scans in the same patients produce the same estimate of disease load and location, and secondly, to study possible association between the bone disease detected by these scans and the effect on disease outcome and survival. Bone disease occurs in about 90% of multiple myeloma (MM) patients. There are no data comparing the new diagnostic modalities with WB-MRI and MIBI in MM.
  
  
  METHODS
  A prospective comparative study between WB-MRI and MIBI scans in assessing bone disease and outcome of MM.
  
  
  METHODS
  Sixty-two consecutive patients with confirmed MM underwent simultaneous WB-MRI (both axial T1 and turbo spin echo short tau inversion recovery (STIR)) and MIBI scans at a single institution from January 2010 to January 2011, and their survival status was determined in January 2012. The median age was 62 years (range 37-88) with a male-to-female ratio of 33 : 29.
  
  
  RESULTS
  In vertebrae and long bones, MRI scan detected more disease compared with MIBI scan (p<0.001) but there was less difference in the skull (p=0.09). In the ribcage, the MIBI scan detected more lytic lesions of the ribs compared with MRI scan (p<0.001). Thirteen of the 62 patients died during the 24-month follow-up. Increased disease detected in all bones by both scans was associated with increased mortality risk (MIBI p=0.001; MRI-STIR p=0.044; but not MRI-T1 p=0.44). In all combined bone groups, the mean MIBI scan results provided a better prediction of mortality than MRI scan over the follow-up period (MRI-T1 vs MIBI p=0.019; MRI-STIR vs MIBI p=0.047).
  
  
  CONCLUSIONS
  Although WB-MRI detected more MM bone disease, MIBI scan predicted overall disease outcome and mortality better than MRI scan. Further studies to define optimum use of these imaging techniques are warranted.
  
  
  BACKGROUND
  The study was registered prospectively in the Australian and New Zealand Clinical Trials Registry at http://www.ANZCTR.org.au under No: ACTRN12609000761268.
authors: Department of Medicine and Clinical Haematology,  Launceston General Hospital, Launceston, Tasmania,  Australia.
authors: Alhossain A
authors: AA
authors: Khalafallah
authors: Andrew
authors: A
authors: Snarski
authors: Robert
authors: R
authors: Heng
authors: Ryan
authors: R
authors: Hughes
authors: Shamsunnaher
authors: S
authors: Renu
authors: Jameen
authors: J
authors: Arm
authors: Richard
authors: R
authors: Dutchke
authors: Iain K
authors: IK
authors: Robertson
authors: Luen B
authors: LB
authors: To